Efficacy of artemether against toxocariasis in mice : parasitological and immunopathological changes in brain, liver, and lung
Toxocariasis is a zoonosis that represents a serious threat to public health particularly in tropical and subtropical areas. Currently, albendazole, the most effective drug for treating visceral toxocariasis, shows moderate efficacy against the larvae in tissues and has some adverse effects. Artemether is an antiparasitic drug mainly used in the treatment of malaria and showed effectiveness against numerous helminthic infections. Besides, it possesses potent anti-inflammatory, antiapoptotic, antifibrotic, and neuroprotective properties. Thus, the study's aim was to investigate artemether's effects in comparison with albendazole on the therapeutic outcome of experimental toxocariasis. For this aim, 140 laboratory-bred mice were divided into four main groups: uninfected control, treatment control, albendazole-treated, and artemether-treated groups. The treatment regimens were started at the 15th dpi (early treatment), and at the 35th dpi (late treatment). The effectiveness of treatment was determined by brain larval count, histopathological, immunohistochemical, and biochemical examination. Artemether showed more effectiveness than albendazole in reducing brain larval counts, markers of brain injury including NF-κB, GFAP, and caspase-3, the diameter and number of hepatic granulomas, hepatic oxidative stress, hepatic IL-6, and TG2 mRNA, and pulmonary inflammation and fibrosis. The efficacy of artemether was the same when administered early or late in the infection. Finally, our findings illustrated that artemether might be a promising therapy for T. canis infection and it could be a good substitution for albendazole in toxocariasis treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Pathogens and global health - 118(2024), 1 vom: 19. Jan., Seite 47-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elgendy, Dina I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albendazole |
|---|
| Anmerkungen: |
Date Completed 04.01.2024 Date Revised 23.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/20477724.2023.2285182 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364705280 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364705280 | ||
| 003 | DE-627 | ||
| 005 | 20240124232000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/20477724.2023.2285182 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM364705280 | ||
| 035 | |a (NLM)37978995 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elgendy, Dina I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of artemether against toxocariasis in mice |b parasitological and immunopathological changes in brain, liver, and lung |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2024 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Toxocariasis is a zoonosis that represents a serious threat to public health particularly in tropical and subtropical areas. Currently, albendazole, the most effective drug for treating visceral toxocariasis, shows moderate efficacy against the larvae in tissues and has some adverse effects. Artemether is an antiparasitic drug mainly used in the treatment of malaria and showed effectiveness against numerous helminthic infections. Besides, it possesses potent anti-inflammatory, antiapoptotic, antifibrotic, and neuroprotective properties. Thus, the study's aim was to investigate artemether's effects in comparison with albendazole on the therapeutic outcome of experimental toxocariasis. For this aim, 140 laboratory-bred mice were divided into four main groups: uninfected control, treatment control, albendazole-treated, and artemether-treated groups. The treatment regimens were started at the 15th dpi (early treatment), and at the 35th dpi (late treatment). The effectiveness of treatment was determined by brain larval count, histopathological, immunohistochemical, and biochemical examination. Artemether showed more effectiveness than albendazole in reducing brain larval counts, markers of brain injury including NF-κB, GFAP, and caspase-3, the diameter and number of hepatic granulomas, hepatic oxidative stress, hepatic IL-6, and TG2 mRNA, and pulmonary inflammation and fibrosis. The efficacy of artemether was the same when administered early or late in the infection. Finally, our findings illustrated that artemether might be a promising therapy for T. canis infection and it could be a good substitution for albendazole in toxocariasis treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a GFAP | |
| 650 | 4 | |a Toxocara canis | |
| 650 | 4 | |a artemether | |
| 650 | 4 | |a caspase-3 | |
| 650 | 4 | |a neuroinflammation | |
| 650 | 4 | |a oxidative stress | |
| 650 | 4 | |a qRT-PCR | |
| 650 | 7 | |a Albendazole |2 NLM | |
| 650 | 7 | |a F4216019LN |2 NLM | |
| 650 | 7 | |a Anthelmintics |2 NLM | |
| 650 | 7 | |a Artemether |2 NLM | |
| 650 | 7 | |a C7D6T3H22J |2 NLM | |
| 700 | 1 | |a Elmahy, Rasha A |e verfasserin |4 aut | |
| 700 | 1 | |a Amer, Alaa Ibrahim Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Hoda A |e verfasserin |4 aut | |
| 700 | 1 | |a Eltantawy, Asmaa Fawzy |e verfasserin |4 aut | |
| 700 | 1 | |a Mansour, Fotouh Rashed |e verfasserin |4 aut | |
| 700 | 1 | |a Salama, Amina M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathogens and global health |d 2012 |g 118(2024), 1 vom: 19. Jan., Seite 47-64 |w (DE-627)NLM217875459 |x 2047-7732 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2024 |g number:1 |g day:19 |g month:01 |g pages:47-64 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/20477724.2023.2285182 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2024 |e 1 |b 19 |c 01 |h 47-64 | ||